Trial Profile
A Phase Ib/II, Open-Label, Multicentre Study to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of AZD9150 Plus Durvalumab Alone or in Combination With Chemotherapy in Patients With Advanced, Solid Tumours and Subsequently in Patients With Non-Small-Cell Lung Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 20 Mar 2024
Price :
$35
*
At a glance
- Drugs Danvatirsen (Primary) ; Danvatirsen (Primary) ; Durvalumab (Primary) ; Carboplatin; Cisplatin; Fluorouracil; Gemcitabine; Paclitaxel
- Indications Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors AstraZeneca
- 14 Mar 2024 Planned End Date changed from 31 Dec 2025 to 6 Jun 2024.
- 02 Nov 2022 Planned End Date changed from 30 Dec 2022 to 31 Dec 2025.
- 06 Dec 2021 Planned End Date changed from 31 Dec 2021 to 30 Dec 2022.